Skip to content

Medical Topic

ApoB and Lp(a): Cardiovascular Longevity and Risk Assessment

ApoB and Lp(a): learn the clinical significance of these two biomarkers in the assessment of atherogenic particle burden, genetic cardiovascular risk, and longevity.

Written by: Dr. Kerem Çağlayan Medically reviewed by: Dr. Kerem Çağlayan First published: September 13, 2026 Last updated: September 29, 2026
ApoB and Lp(a): Cardiovascular Longevity and Risk Assessment
Short answerApoB and lipoprotein(a) [Lp(a)] can provide cardiovascular risk information in addition to the standard lipid panel. ApoB reflects the number of atherogenic particles; Lp(a), on the other hand, is largely genetically determined, and its elevation is important in assessing lifetime risk.

Why is ApoB important?

ApoB more directly represents the total particle burden of LDL and other atherogenic lipoproteins. It can provide additional information, especially in the presence of elevated triglycerides, metabolic syndrome, diabetes, or discordance between LDL-C and clinical risk.

What does Lp(a) tell us?

The Lp(a) level is genetically influenced and relatively stable throughout life. The 2025 ESC/EAS update considers elevated Lp(a) as a cardiovascular risk-enhancing factor. The result alone does not dictate a treatment decision; it is evaluated together with total risk, LDL-C, blood pressure, smoking, diabetes, and family history.

Our approach at our Bodrum clinic

In longevity evaluation, the goal is not solely the question, “Is cholesterol normal?” When necessary, we evaluate ApoB, Lp(a), triglyceride/HDL ratio, and other cardiometabolic markers together; we interpret the results within the individual’s absolute risk.

Vascular age and PWV → · Longevity main guide →

Last medical review: September 13, 2026
Warning: Laboratory results must be interpreted within the individual clinical context.

Medical editorial information

This content has been medically reviewed and approved by Dr. Kerem Çağlayan. It is intended for general education and does not replace an individual diagnosis or treatment plan.

Related content

Content

CliNext – Privacy Policy and KVKK Clarification Text

Clarification regarding the CliNext clinical follow-up system, patient records, WhatsApp communication, processing of health data, artificial intelligence-supported evaluations, and rights under the KVKK.
The 80% Rule in Healthy Eating: A Sustainable Dietary Pattern Instead of a Perfect Diet

Medical Topic

The 80% Rule in Healthy Eating: A Sustainable Dietary Pattern Instead of a Perfect Diet

Does every meal have to be flawless in healthy eating? We evaluate the 80% approach in terms of the Mediterranean-style diet, ultra-processed foods, sustainability, and clinical nutrition.
Can the Shingles Vaccine Reduce Dementia Risk? Natural Experiments, Shingrix, and Alzheimer’s Research

Medical Topic

Can the Shingles Vaccine Reduce Dementia Risk? Natural Experiments, Shingrix, and Alzheimer’s Research

The association between the shingles vaccine and a lower risk of dementia has been replicated in data from Wales, Canada, and the US. We examine the power, limitations, and clinical significance of natural experiments.